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According to the 2005–2006 National Health and Nutrition 
Examination Survey, 29% of all US adults are hypertensive with 
respective prevalences of 41%, 28%, and 22% among African, 
Caucasian, and Hispanic American adults.1 Elevated blood 
pressure (BP) is the most common modifiable risk factor for 
cardiovascular disease. Thus, there is great interest in identi-
fying the underlying genetic and environmental determinants. 
In 1995 the National Heart, Lung, and Blood Institute estab-
lished a collaboration of four multicenter networks, known as 
the Family Blood Pressure Program (FBPP), to investigate the 
genetic determinants of interindividual BP variation in Asians, 
African Americans, Mexican Americans, and Caucasians.2 
The FBPP collaboration yielded statistical power and diversity 
unmatched in any individual study.3
The complete FBPP resource includes 13,516 individuals 
with microsatellite genotype data from two temporally distinct 
study phases (phases 1 and 2 were conducted from 1995–2000 
to 2000–2005, respectively). We report here a linkage analy-
sis of the complete pooled FBPP data, which has considerably 
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Background
a preliminary genome-wide linkage analysis of blood pressure in the 
Family Blood Pressure Program (FBPP) was reported previously. We 
harnessed the power and ethnic diversity of the final pooled FBPP 
dataset to identify novel loci for blood pressure thereby enhancing 
localization of genes containing less common variants with large 
effects on blood pressure levels and hypertension.
Methods
We performed one overall and 4 race-specific meta-analyses of 
genome-wide blood pressure linkage scans using data on 4,226 
african-american, 2,154 asian, 4,229 caucasian, and 2,435 Mexican-
american participants (total N = 13,044). Variance components 
models were fit to measured (raw) blood pressure levels and two 
types of antihypertensive medication adjusted blood pressure 
phenotypes within each of 10 subgroups defined by race and 
network. a modified Fisher’s method was used to combine the 
P values for each linkage marker across the 10 subgroups.
results
Five quantitative trait loci (QTLs) were detected on chromosomes 
6p22.3, 8q23.1, 20q13.12, 21q21.1, and 21q21.3 based on significant 
linkage evidence (defined by logarithm of odds (lod) score ≥3) in at least 
one meta-analysis and lod scores ≥1 in at least 2 subgroups defined by 
network and race. The chromosome 8q23.1 locus was supported by 
asian-, caucasian-, and Mexican-american-specific meta-analyses.
conclusions
The new QTLs reported justify new candidate gene studies. They may 
help support results from genome-wide association studies (GWaS) 
that fall in these QTL regions but fail to achieve the genome-wide 
significance.
Keywords: blood pressure; genetics; hypertension; linkage;  
meta-analysis; QTL
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more power for detecting quantitative trait loci (QTLs) for 
BP. Indeed, this investigation reports multiple QTLs in com-
parison with previous reports based on various subsets of the 
interim data.4–6
The FBPP database permits an overall meta-analysis of all 
10 subgroups defined by network and race and 4 race-specific 
meta-analyses (three cohorts each of African Americans and 
Caucasians, 2 cohorts of Mexican Americans, and 2 cohorts 
of Asians– Japanese and Chinese). We conducted all analyses 
using the observed BP as well as two types of antihypertensive 
medication adjusted systolic blood pressure (SBP), diasto-
lic blood pressure (DBP), mean arterial pressure (MAP), and 
pulse pressure (PP) phenotypes to search for novel BP QTLs. 
Recent genome-wide association studies (GWAS) have iden-
tified a number of common variants associated with BP and/
or hypertension. However, they mostly include individuals 
of European descent and account for only a small fraction of 
the phenotypic variance.7 Therefore, there is a need to identify 
genomic regions that harbor rare variants with relatively large 
effect sizes. Detecting such regions could lead to novel findings 
that complement the current GWAS results.
Methods
Subjects. The FBPP pooled data derive from the four sepa-
rate multicenter networks: GenNet, Genetic Epidemiology 
Network of Atherosclerosis (GENOA), Hypertension Genetic 
Epidemiology Network (HyperGEN), and Stanford Asian 
Pacific Program in Hypertension and Insulin Resistance 
(SAPPHIRe)2 (Table 1). A detailed description of each cohort 
can be found elsewhere.2 All FBPP studies were approved by 
their respective institutional review committees and all partici-
pants gave informed consent. All networks recruited families 
ascertained through individuals with high or low BP. GenNet 
recruited African-American, Caucasian, and Mexican-
American nuclear families ascertained through young-/mid-
dle-aged probands with untreated high-normal BP. GENOA 
recruited African-American and Caucasian sibships contain-
ing at least two hypertensive members, Mexican-American 
table 1 | characteristics of subjects in linkage analysis
Network Race Nfam Sex N
a Mean age 
(years)
HT% Meds% Mean BMI 
(kg/m2)
Mean SBP 
(mm Hg)
Mean DBP 
(mm Hg)
Mean MAP 
(mm Hg)
Mean PP 
(mm Hg)
GenNet Black 266 F 475 42 38 27 32.7 126.1 76.8 93.2 49.3
M 320 39 30 11 27.1 129.2 79.0 95.7 50.2
hispanic 184 F 492 36 11 9 29.0 109.4 60.5 76.8 48.9
M 301 33 13 8 28.1 116.2 63.3 80.9 52.9
caucasian 226 F 537 46 33 26 29.2 119.8 67.7 85.1 52.2
M 434 44 34 23 28.9 127.1 72.7 90.8 54.4
Total 676 — 2,559 41 27 18 29.4 121.0 69.7 86.8 51.2
GENOa Black 518 F 1,155 57 73 64 32.0 130.3 69.1 89.5 61.2
M 521 59 68 54 28.3 131.1 73.9 92.9 57.2
hispanic 392 F 969 55 50 39 31.5 126.9 68.3 87.9 58.6
M 673 55 48 29 29.6 129.6 74.4 92.8 55.2
caucasian 478 F 768 55 73 67 30.3 130.8 72.8 92.2 58.0
M 640 56 78 64 30.3 135.6 79.9 98.4 55.7
Total 1,388 — 4,726 56 65 54 30.6 130.4 72.3 91.6 58.2
hyperGEN Black 522 F 1,159 47 71 67 33.5 128.7 73.1 91.6 55.6
M 596 46 65 56 29.7 130.8 77.1 95.0 53.7
caucasian 430 F 968 54 61 59 29.2 120.3 66.9 84.7 53.5
M 882 52 61 57 29.0 122.8 72.5 89.3 50.3
Total 952 — 3,605 50 65 60 30.6 125.4 72.0 89.8 53.4
SaPPhIRe chinese 406 F 871 52 60 53 24.8 127.4 73.7 91.6 53.7
M 695 50 70 57 25.9 133.2 81.9 99.0 51.4
Japanese 158 F 346 59 82 77 26.4 132.7 75.3 94.4 57.5
M 242 59 84 75 27.4 136.1 83.6 101.1 52.4
Total 564 — 2,154 53 69 60 25.7 131.1 77.8 95.6 53.3
TOTaL 3,580 13,044 51 58 49 29.7 127.1 72.4 90.6 54.7
BMI, body mass index; DBP, diastolic blood pressure; HT%, percent sample who are hypertensive; GENOA, Genetic Epidemiology Network of Atherosclerosis; HyperGEN, Hypertension 
Genetic Epidemiology Network; MAP, mean arterial pressure; Meds%, percent sample who are on antihypertensive/diuretic medications. Nfam, number of families; N, sample size; 
PP, pulse pressure; SAPPHIRe, Stanford Asian Pacific Program in Hypertension and Insulin Resistance; SBP, systolic blood pressure; .
aThe number of individuals appearing in both the phenotype and genotype datasets. 12,995 individuals have some microsatellite data, 11,932 have one or more non-outlier covariate-
adjusted blood pressure values, and 13,031 have either some microsatellite or some non-outlier covariate adjusted phenotype information.
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sibships containing at least two adult onset diabetic siblings 
and all full siblings of each index pair. HyperGEN recruited 
African-American and Caucasian hypertensive siblings, their 
parents, and one or more of a sibling’s untreated offspring; 
sibships containing one severely hypertensive member were 
ascertained preferentially. SAPPHIRe recruited Chinese and 
Japanese sib pairs that were highly concordant or discordant 
for hypertension.
Genotyping. The Mammalian Genotyping Service in Marshfield, 
WI, performed all genome-wide scans.8 For all cohorts except 
GenNet Mexican Americans, we used 362 autosomal mark-
ers (with average intermarker distance 9.5 cM) after removing 
those with high (>70%) missing rates, that were duplicates of 
the same position, or were mapped to multiple locations in the 
genome. GenNet Mexican Americans were genotyped much 
later, using a subsequent (marker) screening set. After quality 
control, this yielded 372 Marshfield autosomal markers (with 
average intermarker distance 9.4 cM). Most (71%) of the GenNet 
Mexican-American markers overlapped or shared a genetic dis-
tance with markers used in other cohorts. Family relationships 
were verified using graphical representation of relationships 
and affected sibpair exclusion mapping, while Mendelian errors 
were removed via MapMaker/SIBS and Pedcheck.4
Phenotype adjustment. All networks used a consistent BP 
measurement protocol.4,6 The pooled FBPP dataset includes the 
average of three sitting SBP or DBP measurements taken using 
Dinamap (for 504 GenNet African Americans and 2 GenNet 
Caucasians, the measurements were taken using the Omron). 
MAP was estimated by the sum of two-thirds the average DBP 
and one-third the average SBP. PP was computed as the differ-
ence between the average SBP and DBP. We excluded the BP 
phenotypes of participants with hypertension diagnosed after 
age 60 or with BMI, SBP, DBP, MAP, or PP values four or more 
standard deviations from the mean of the subgroup (based on 
network, race, and sex).
The observed blood pressures (SBP, DBP, MAP, PP) of all 
individuals, irrespective of antihypertensive medication use, 
composed the “raw” set of phenotypes. Next, we assumed 
the measured BP of individuals treated with antihypertensive 
medications was lower on average than if the individuals had 
not been treated. Since any attempt to adjust BP for medica-
tion use is only an approximation, we calculated two differ-
ent sets of “medication adjusted” BP phenotypes. The “+10/5” 
medication adjusted values9 were derived by adding 10 mm Hg 
to SBP and 5 mm Hg to DBP (only for those known to be tak-
ing medications). Similarly, the “+15/10” medication adjusted 
values10 were obtained by adding 15 mm Hg to SBP and 
10 mm Hg to DBP. The medication adjusted PP and MAP were 
calculated from the medication adjusted SBP and DBP values. 
The observed BP phenotypes were used for those untreated or 
with unknown medication status. Only one medication adjust-
ment was performed for PP since both “+10/5” and “+15/10” 
result in the same values for all individuals (obtained by add-
ing 5 mm Hg to PP for medication users).
We narrowed our search to primarily hypertension genes 
instead of genes primary for a comorbidity (such as BMI) and 
secondary to hypertension. Therefore, phenotypes were also 
adjusted for BMI in addition to age, age-squared, age-cubed, 
and field center within each subgroup (defined by network, 
race, and sex), retaining terms significant at 5%. The residual 
phenotypes were standardized to a mean of 0 and s.d. of 1. We 
excluded any covariate-adjusted phenotype value that is 4 or 
more s.d.s away from the mean of the subgroup (fewer than 3 
values were excluded for any phenotype in any group).
Statistical analysis. Genome-wide linkage analyses were car-
ried out within subgroups defined by network and race (after 
male and female blood pressure residuals were combined) 
using the multipoint variance components method as imple-
mented in Merlin.11 We used sex-averaged genetic distances 
from the Marshfield map and allele frequencies estimated from 
our samples. We tested all markers for additive genetic vari-
ance due to a QTL. For GenNet Mexican-American partici-
pants, we completed the linkage analysis at the locations of the 
372 genotyped markers plus the 90 markers exclusive to the 9 
other network-race subgroups. Overall and race-specific meta-
analyses were conducted by combining P values of the 362 
common markers using a modification of Fisher’s method.12
Definition of a QTL. We define a QTL as a genomic segment 
yielding a significant logarithm of odds (lod) score (≥3) in any 
meta-analysis in addition to suggestive evidence (with a lod 
score ≥1) in at least two subgroups defined by network and 
race for any blood pressure phenotype.
results
After excluding singletons, our analysis sample (N = 13,044) 
included 2,154 Asians, 4,226 African Americans, 2,435 
Mexican Americans, and 4,229 Caucasians. Table 1 displays 
the summary statistics for each network stratified by race and 
sex after removal of BP outliers, BMI outliers, and those with 
hypertension diagnosis after age 60.
Multipoint variance components lod scores are shown in 
Table 2. Loci are included if they yielded lod scores ≥3 (in 
bold) for any phenotype in any analysis (the overall meta-
analysis, race-specific meta-analysis, or network-race specific 
analysis). Six of the nine distinct loci presented in Table 2 are 
significantly linked to pulse pressure. Five of the nine loci met 
our (stringent) definition of a QTL: one QTL from each of the 
overall, African-American, and Hispanic meta-analyses, and 
two from the Caucasian meta-analysis (see Supplementary 
Data online for heritabilities at QTLs). All Asian meta- and 
cohort-specific linkage analyses yielded maximum lod scores 
≤2.57. Thus, this ethnic group is represented in Table 2 only 
through its contribution to the overall meta-analysis.
Table 3 shows the network-race subgroups contributing evi-
dence to each of the five QTLs. Of the five loci with meta-analysis 
lod scores ≥3, the chromosome 8q23.1 (119.22 cM) locus had 
two or more race-specific meta-analysis lod scores ≥1. Figure 1 
displays the overall and race-specific meta-analysis linkage 
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evidence between raw DBP and chromosome 8 (positions 
77–165 cM). This overall meta-analysis QTL was supported by 
Asians, Caucasians, and Mexican Americans. African Americans 
failed to show any corroborating evidence at this locus.
The African-American meta-analysis QTL on chromo-
some 6p22.3 (42.27 cM) was substantiated by GenNet and 
HyperGEN African Americans while the Caucasian meta-
analysis QTL on chromosome 21q21.1(13.05 cM) was sup-
ported by all three Caucasian studies. The fourth QTL on 
chromosome 21q21.3 (24.73 cM) was supported by all three 
Caucasians cohorts and HyperGEN African Americans. The 
Hispanic meta-analysis locus at 20q13.12 (62.32 cM) achieved 
significant linkage in GENOA Mexican Americans and had 
a lod score ≥1 for GenNet Caucasians. Figure 2 displays the 
table 3 | cohort-specific linkage results (lod scores ≥1) for the five blood pressure Qtls
Meta Chr Position Cohort
Phenotypesa with  
lod score ≥1
Maximum lod score
Value Phenotype
Overall 8 119.22 GenNet caucasians SBP, DBP, MaP 1.84 +5 DBP
GenNet Mexican americans SBP 1.64 +10 SBP
GENOa Mexican americans MaP 1.77 Raw MaP
SaPPhIRe chinese DBP, MaP 1.52 Raw DBP
SaPPhIRe Japanese DBP 1.11 Raw DBP
african americans 6 42.27 GenNet african americans PP 2.25 Raw PP
hyperGEN african americans PP 1.64 Raw PP
caucasians 21 13.05 GenNet caucasians SBP, PP 1.54 +15 SBP
GENOa caucasians SBP, DBP, MaP, PP 3.06 Raw PP
hyperGEN caucasians PP 1.17 Ma PP
caucasians 21 24.73 GenNet caucasians SBP, PP 1.71 +15 SBP
GENOa caucasians SBP, PP 2.23 Ma PP
hyperGEN african americans SBP, DBP, MaP 1.60 +10/5 MaP
hyperGEN caucasians DBP, MaP 1.26 +5 DBP
Mexican americans 20 62.32 GenNet caucasians SBP 1.52 Raw SBP
GENOa Mexican americans SBP, MaP, PP 5.43 Raw PP
aFor the phenotype(s) listed, lod scores≥1 for any combination of raw, +10/5 medication adjusted, and/or +15/10 medication adjusted.
DBP, diastolic blood pressure; GENOA, Genetic Epidemiology Network of Atherosclerosis; HyperGEN, Hypertension Genetic Epidemiology Network; lod, logarithm of odds; MAP, mean 
arterial pressure; PP, pulse pressure; QTL, quantitative trait loci; SAPPHIRe, Stanford Asian Pacific Program in Hypertension and Insulin Resistance; SBP, systolic blood pressure.
table 2 | genome-wide significant loci from meta-analysis and cohort-specific linkage analysis
Race Analysis Chr Pos (cM) SBP DBP MAP PP
Raw +10 MA +15 MA Raw +5 MA +10 MA Raw +10/5 MA +15/10 MA Raw MA
all Meta 8 119.22 1.80 1.92 2.04 3.12 2.47 1.61 2.52 2.65 2.15 0.43 0.41
african 
americans
Meta 6 42.27 0.85 0.91 0.86 0.01 0.00 0.02 0.04 0.13 0.16 3.76 3.23
hyperGEN 1 212.44 0.88 1.39 1.55 0.00 0.05 0.17 0.17 0.41 0.61 2.82 3.16
caucasians Meta 21 13.05 3.12 3.17 2.87 0.96 0.76 0.56 1.73 1.52 1.24 4.36 4.55
GENOa 21 13.05 2.83 2.20 1.73 1.24 0.76 0.45 2.00 1.41 0.96 3.06 2.69
Meta 21 24.73 2.15 2.86 3.01 1.08 0.81 0.57 1.57 1.46 1.18 2.93 3.60
GenNet 20 95.70 2.39 2.58 2.89 1.37 1.62 1.98 2.52 3.12 3.09 1.03 0.90
Mexican 
americans
Meta 20 62.32 1.91 1.75 1.50 0.44 0.53 0.46 1.28 1.07 0.92 4.40 3.98
GENOa 20 62.32 2.69 1.81 1.44 0.91 0.69 0.54 1.60 0.87 0.59 5.43 4.68
GenNet 11 105.74 1.24 0.88 0.84 1.30 2.46 3.09 2.69 2.56 2.63 0.37 0.24
GENOa 17 89.32 2.42 2.66 2.51 0.50 0.50 0.56 1.29 1.36 1.27 3.04 3.15
Lod scores ≥3 are indicated in bold.
+10 MA, Raw+10 for antihypertensive/diuretic takers; +10/5 MA, phenotype calculated from +10 MA SBP and +5 MA DBP; +15 MA, Raw+15 for antihypertensive/diuretic takers; 
+15/10 MA, phenotype calculated from +15 MA SBP and +10 MA DBP; +5 MA, Raw+5 for antihypertensive/diuretic takers; DBP, diastolic blood pressure; GENOA, Genetic Epidemiology 
Network of Atherosclerosis; HyperGEN, Hypertension Genetic Epidemiology Network; lod, logarithm of odds; MAP, mean arterial pressure MA, medication adjusted phenotype; 
PP, pulse pressure; Raw, measured phenotype; SBP, systolic blood pressure.
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race-specific meta-analysis results for the phenotypes with the 
highest lod scores at their respective linkage peaks on chromo-
somes 6, 20, and 21.
The remaining four loci on chromosome 1q31.3 (212.44 cM), 
11q23.1 (105.74 cM), 17q24.2 (89.32 cM), and 20q13.32 
(95.70 cM) presented in Table 2 had significant cohort-specific 
lod scores but none achieved a significant meta-analysis lod 
score. All QTLs except 17q24.2 had lod scores ≥1 in at least 
one additional subgroup defined by network and race (see 
Supplementary Data online). Finally, we identified a total of 47 
secondary QTLs, each one supported by a lod score ≥2 in any 
of the subgroups or meta-analyses (see Supplementary Data 
online). All QTLs were located on 17 of the 22 autosomes.
discussion
These are both exciting and challenging times to undertake 
genetic dissection of common complex diseases and disease 
related traits. They are exciting because the number of prom-
ising tools available is constantly on the increase and chal-
lenging because the current GWAS findings for BP explain a 
very small fraction of the total heritability. For example, recent 
meta-analyses from two large consortia (Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) 
and Global Blood Pressure Genetics Consortium (GBPGEN)) 
identified 13 loci through GWAS that collectively explain <2% 
of SBP and DBP variances.13,14 There is growing consensus that 
this is largely because of our reliance on “common variants” 
to explain the genetic heritability of common phenotypes. 
Finding the missing heritability is the formidable challenge 
we face.7 While linkage analysis generally failed to advance the 
field of common complex traits, we believe that it has a unique 
role to play in the current debate. In the past, QTLs identified 
through linkage analysis have been followed up through com-
mon variants at positional candidate genes. It is more likely 
that QTLs are localizing genes with relatively low frequency 
variants having considerably larger effect sizes. Candidate 
gene-based resequencing suggests that less common genetic 
variants contribute to the phenotypic variance of common dis-
eases.15 Seen in this light, we believe that the QTLs reported 
here for BP make an important contribution.
By harnessing the large sample size of the complete FBPP 
database, we were able to identify five strong QTLs for BP. 
The most promising QTL for DBP on chromosome 8q23.1 
(119.22 cM, marker = D8S1132, lod = 3.12) was identified by 
the overall meta-analysis of all 10 subgroups defined by net-
work and race. The main finding in Asians, especially given 
the limited sample size of the SAPPHIRe Japanese cohort 
(N = 588), was their support for this QTL. Both SAPPHIRe 
Chinese (lod = 1.52) and SAPPHIRe Japanese (lod = 1.11) are 
major contributors to linkage at D8S1132. The maximum lod 
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Figure 1 | Overall and race-specific meta-analysis results for diastolic blood 
pressure on chromosome 8. lod, logarithm of odds.
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Figure 2 | The race-specific meta-analysis linkage evidence for chromosomes 
6, 20, and 21. (a) The african-american meta-analysis linkage evidence 
between pulse pressure (PP) and chromosome 6. (b) The Mexican-american 
meta-analysis linkage evidence between pulse pressure and chromosome 20.  
(c) The caucasian meta-analysis linkage evidence between medication 
adjusted PP and chromosome 21, as well as +15 medication adjusted systolic 
blood pressure (SBP) and chromosome 21. lod, logarithm of odds.
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score of any Asian meta-analysis across all phenotypes and 
markers was 2.57 for DBP on chromosome 8q22.2 at 110.2 cM 
(8.14 Mbps from the overall meta-analysis peak). The same 
genomic segment (8q22–23) was previously linked to essential 
hypertension in 173 affected individuals in a 2,180-member 
pedigree in Campora, Italy.16 Significant association between 
SBP and marker D8S592 on chromosome 8q24.11 (125.3 cM) 
was reported earlier in GENOA Caucasians.17 While we 
lacked significant evidence for this QTL in African Americans, 
a GWAS of 1,017 normotensive African Americans identified 
a significant (P = 1.59 × 10−8) association between SBP and 
rs17365948 on chromosome 8q22.3 (5 Mb from our marker 
D8S1132).18 This result was not supported in the GWAS 
replication sample of 980 West Africans (P = 0.507). A dis-
parity in minor allele frequencies (MAFs) between the African-
American (MAF = 0.113) and West African (MAF = 0.005) 
samples could be responsible in part for the discrepancy in 
results.18 Moderate evidence for linkage (lod = 1.74) was 
found between D8S1132 and the log-transformed DBP in sub-
jects from rural Nigeria.19 The significant SNP (rs17365948) 
is in the intron of YWHAZ, which may have a role in regu-
lating insulin sensitivity (http://genome.ucsc.edu).20 Other 
candidate genes in this region include ANGPT1, ZFPM2, and 
OXR1. Angiopoietin, encoded by ANGPT1, induces pulmo-
nary hypertension in rodents, is increased in humans suffering 
from essential hypertension which decreases after successful 
antihypertensive treatment.16,21 ZFPM2 codes a zinc finger 
protein that may modulate the activity of the GATA proteins 
that help regulate mammalian hematopoiesis and cardiogen-
esis.20 Oxidation resistance 1 (OXR1), the closest gene, may 
help prevent oxidative damage.20
The QTL for PP on chromosome 6p22.3 (42.27 cM, 
marker = D6S2439, lod = 3.76) from the African-American-
specific meta-analysis has also been implicated for SBP in a 
GWAS of normotensive African Americans.18 The significant 
(P = 3.42 × 10−9) association between SBP and rs16877320 
on chromosome 6p22.3 (8 Mb from our marker D6S2439) 
failed to replicate in 980 West Africans (P = 0.781).18 Again 
a discrepancy in MAF could be responsible in part. The MAF 
of the SNP in the African-American and West African sam-
ples were 0.132 and 0.023, respectively.18 Linkage studies have 
provided evidence for this locus with other BP phenotypes in 
other ethnicities. Postural changes in SBP (lod = 1.9) and DBP 
(lod = 1.7) were both linked, at least tentatively, to D6S2439 in 
498 HyperGEN Caucasian hypertensive sibpairs.22 Potential or 
significant linkage of SBP within 10 cM of D6S2439 has been 
demonstrated in western Europeans (52 cM, lod = 1.97)23 and 
GENOA Hispanics (34.2 cM, P = 0.002).17 Early studies hinted 
that a genomic segment near HLA class II was linked to essen-
tial hypertension.24 D6S2439 is ~5.6 Mbps from HLA-A and 
8.2 Mbps from HLA-DRB1. D6S2439 is also 7.2 Mbps from 
the tumor necrosis factor-α gene which was associated with 
obesity-related hypertension in nonmorbidly obese French-
Canadians.25 Tumor necrosis factor amplifies the production 
of angiotensinogen and endothelin-125; the latter is a potent 
vasoactive peptide.24
The two QTLs at 21q21.1 (13.05 cM, marker = D21S1437) for 
PP (lod = 4.55) and SBP (lod = 3.17) and 21q21.3 (24.73 cM, 
marker = D21S2052) for PP (lod = 3.60) and SBP (lod = 3.01) 
may implicate one or more BP associated genes. The confi-
dence interval for PP subsumes that for SBP, although different 
genetic causes may be contributing to SBP and PP. The number 
of peaks encompassing these two neighboring markers is inde-
terminate but sufficient supporting evidence is found in the 
intervening genomic region. A previous analysis of log-trans-
formed pulse pressure in the FBPP phase 1 pooled data identi-
fied a significant locus in Caucasians (lod = 4.3) at 18 cM and 
combined African Americans and Caucasians (lod = 3.2) at 
19 cM.4 The same analysis yielded suggestive linkage in all racial 
groups combined (lod = 2.1) at 21 cM and GENOA Caucasians 
(lod = 2.2) at 17 cM.4 A suggestive linkage (lod = 2.44) between 
21q21 and MAP was established in Mexican Americans from 
the San Antonio Family Heart Study.26 A significant associa-
tion between SBP and D21S2052 at 24.73 cM was previously 
reported in GENOA Mexican Americans.17 A promising 
region for DBP in proximity to 24.73 cM was also discovered 
during a secondary analysis of low concordant sibpairs from 
Anqing, China.27 Admixture mapping methods have indicated 
that 21q21 may contain genes influencing risk of hyperten-
sion in African Americans.28,29 In the admixture mapping 
analysis of Dallas Heart Study sample using 1,890 ancestry 
informative SNPs, the 1-unit Z score drop region spans from 
8 to 30 cM,29 which is consistent with the region identified 
in this study. A GWAS of normotensive African Americans 
identified a suggestive (P = 5.73 × 10−6) association between 
DBP and rs2823756 on chromosome 21q21.1 (4 Mb from 
our marker D21S1437).18 Perhaps clues about potential can-
didate genes can be gleaned from the suggestive bivariate 
linkage evidence (lod = 3.03) of D21S1437 on chromosome 
21q21.1 (13.05 cM) with C-reactive protein and fibrinogen in 
GENOA Caucasians.30 Both C-reactive protein and fibrinogen 
are inflammation indicators and predictors of cardiovascular 
disease.31,32 C-reactive protein inhibits endothelial nitric oxide 
synthase expression, while fibrinogen helps determine plasma 
viscosity30 and is a member of the coagulation cascade.
Our fifth QTL for PP on chromosome 20q13.12 (62.32 cM, 
marker = D20S481, lod = 4.40) was discovered due to the 
inclusion of Mexican-American participants. This QTL was 
linked previously to pulse pressure in GENOA Hispanics 
(lod = 4.4)4 and the slope and curvature of repeated measures 
of SBP over multiple visits in the Framingham Heart Study.33 
Suggestive linkage for SBP variation was discovered near this 
locus in GENOA Caucasian discordant sibpairs.34 A tentative 
linkage (lod = 1.75) between SBP and chromosome 20q13 was 
observed in a sample from the isolated Croatian island Vis.35 
A single-nucleotide polymorphism, located 4.2 Mbps from 
D20S481, was associated with SBP in both the Vis popula-
tion and the British 1958 Birth Cohort. Barbalic et al. argue 
that the potassium voltage gate channel gene (KCNB1) and 
the prostaglandin I2 (prostacyclin) synthase gene (PTGIS) are 
candidates for the association.35 KCNB1 belongs to the volt-
age-gated potassium channel family that is involved in insu-
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lin secretion, heart rate regulation, neurotransmitter release, 
and more. PTGIS, 4.35 Mbps from our D20S481, helps cata-
lyze prostaglandin H2 to the vasodilator and platelet aggrega-
tion inhibitor prostacyclin.35 Japanese participants of the Suita 
Study with particular genotypes in the promoter region of the 
human prostacyclin synthase gene had significantly higher 
SBP, PP, and odds of hypertension.36
The variable effect of antihypertensive medication adjust-
ment on linkage evidence can be seen in Table 2. The +15/10 
and +10/5 adjustments correspond to both increased (e.g., 
+15 SBP in the Caucausian meta-analysis of chromosome 
21 position 24.73 cM) and decreased (e.g., +10 DBP in the 
overall meta-analysis of chromosome 8 position 119.22) lod 
scores. This fluctuation in BP linkage evidence by medica-
tion adjustment scheme has been well-documented.9,10,37 
The analysis of raw (measured) BP values obscures the con-
tribution of treated individuals to the familial component of 
BP.9 We used medication adjustment to infer the underlying 
pretreatment BP value.10 The BP values of treated individuals 
were augmented by a constant value to combat negative bias 
and the resultant loss of power.10 This adjustment method 
works well in a variety of settings10 but is an approxima-
tion that may over- or underestimate the underlying BP and 
therefore the exact effect on the lod score is difficult to pre-
dict. Thus, we present the linkage evidence from the raw and 
medication adjusted analyses hoping that they will bracket 
the correct results.
Characteristics of hypertension such as prevalence, age of 
diagnosis, and severity differ among ethnic groups.38 The fail-
ure to replicate a significant locus across racial groups within 
the same study does not necessarily suggest that the genetic 
effect is race-specific. A hypertension susceptibility gene may 
have the same underlying biological function across races but 
varying etiological variants or interacting genetic/environ-
mental modulators may lead to different observed effect sizes 
and hence the power to detect the gene within each race.39 
Specifically, the allelic heterogeneity of a locus across popula-
tions may be a reason why association results sometimes fail to 
replicate across studies. The 8q23.1 locus substantiated by all 
non-African-American FBPP cohorts, normotensive African 
Americans from Washington DC, and a sample of Nigerians 
shows the complicated interplay between genes and envi-
ronment. Integrating these results from linkage with GWAS 
results to generate testable hypotheses is a logical next step. 
The so-called missing heritability7 may be found only when 
all hypertension susceptibility loci (both common and rare), 
environmental factors, and relevant gene-gene and gene–
environment interactions are fully identified and modeled 
together. Our linkage findings may advance us toward this goal 
by providing supporting evidence for potential BP loci that fail 
to meet genome-wide significance in current GWAS studies 
due to small effect sizes. Results reported in this study can be 
used to derive weighting schemes for interpreting results from 
GWAS.7 We conclude that low frequency variants in genes 
localized in the QTLs may contribute to the missing heritabil-
ity of hypertension.
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